Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04707872 · ClinicalTrials.gov registry record

Trifecta-Heart cfDNA-MMDx Study

A clinical trial of Heart Transplant Rejection, sponsored by University of Alberta.

Recruiting
Registry status
300
Enrollment target
12
Study locations

NCT04707872: Recruiting study of Heart Transplant Rejection, sponsored by University of Alberta.

NCT04707872 is a study of Heart Transplant Rejection that is actively recruiting participants, run by University of Alberta. The registered enrollment target is 300 participants, below the 681-participant average among 5 other Heart Transplant Rejection trials with a reported enrollment target (56% lower). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04707872, a study of Heart Transplant Rejection, is actively recruiting participants, sponsored by University of Alberta.

RECRUITING
Registry status
300 participants
Enrollment target
12
Study locations

Study Summary

Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood transplant recipient and the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from heart transplants.

Primary Outcome

Set DD-cfDNA test cut-off values against the probability of T cell-mediated rejection in the biopsy as reported by MMDx. Calibration of DD-cfDNA test cut-off values against the probability of T cell-mediated rejection in the biopsy as reported by MMDx.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST MMDx diagnostic test
  • DIAGNOSTIC_TEST Prospera
  • DIAGNOSTIC_TEST HLA antibody

Study Locations (12)

Other

  • Cardiac Transplantation Laboratory, The Victor Chang Cardiac Research Institute - Darlinghurst
  • Institute for Clinical and Experimental Medicine - IKEM Videnska 1958/9 - Prague
  • Heart Failure and Heart Transplant Unit, University of Bologna - Bologna
  • Silesian Center for Heart Diseases (Ś!ąskie Centrum Chorób Serca w Zabrzu - Zabrze
  • Advanced Heart Failure Transplant Unit - A Coruña

Arkansas

  • Baptist Health Institute for Research and Innovation - Little Rock

Florida

  • Tampa General Hospital, 409 Bayshore Blvd. - Tampa

New Jersey

  • Columbia University Medical Center, Columbia Interventional Cardiovascular Care - West New York

New York

  • Montefiore Medical Center, 3319 Rochambeau Avenue, 2nd FL - The Bronx

Texas

  • Annette C. and Harold C. Simmons Transplant Institute, BaylorScott&White Research Institute - Dallas

Utah

  • Cardiovascular Medicine, University of Utah Health - Salt Lake City

Alberta

  • Division of Cardiology, University of Alberta - Edmonton

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2021-06-01
Est. Completion 2027-07
University of Alberta

19 total trials

What NCT04707872 shows while recruiting

NCT04707872 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 681-participant average among 5 other Heart Transplant Rejection trials with a reported enrollment target (56% lower).

The record links to 1 condition, with Heart Transplant Rejection appearing as the primary indexed condition, and to 3 interventions - of which MMDx diagnostic test is the first listed.

NCT04707872 lists 12 locations in 8 states (Other, Arkansas, Florida).

Frequently Asked Questions

What is clinical trial NCT04707872 about?

NCT04707872 is a clinical study titled "Trifecta-Heart cfDNA-MMDx Study". Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood transplant recipient and the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from heart transplants.

What is the current status of trial NCT04707872?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2021-06-01. Estimated completion is 2027-07.

What conditions does trial NCT04707872 study?

This clinical trial studies the following conditions: Heart Transplant Rejection.

What interventions are being tested in trial NCT04707872?

The interventions under investigation include: MMDx diagnostic test (DIAGNOSTIC_TEST), Prospera (DIAGNOSTIC_TEST), HLA antibody (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT04707872?

This trial is sponsored by University of Alberta, which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04707872 being conducted?

This trial has 12 study locations across Arkansas, Florida, New Jersey, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Transplant Rejection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04707872, the US trial registry maintained by the National Library of Medicine. NCT04707872 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.